SCORE2

Clinical Trials // Michael Altaweel // Ongoing // Retinal Vein Occlusion // Sep 30 2020

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

  • Sponsor: NIH
  • Principal Investigator: Michael Altaweel, MD, MPH
  • Study Coordinator: Angie Adler

Study objective:

This study will determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with CRVO, with the primary outcome of visual acuity measured at 6 months.

Study design:

Patients will be randomly assigned to one out of two study treatment groups. The study will compare aflibercept (2 mg) every 4 weeks to bevacizumab (1.25 mg) every 4 weeks.

Diagnosis and Key Eligibility Criteria:

At least 18 years of age with center-involved macular edema secondary to CRVO in the study eye. Previous treatment with anti-VEGF therapy is allowed with a 2 month washout period. Previous investigational therapy is allowed with some restrictions.

Duration of study: Approximately 1 year.

For more information, contact Angie Adler 608-265-7557.